Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1 3Phase NA 2Phase 4 2

Status

Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Other 1Gynecologic 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunction, Physiological 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Depression 1Carcinoma, Ovarian Epithelial 1Atrophic Vaginitis 1Anxiety Disorders 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Dehydroepiandrosterone × Clear all
NCT06611514 2024-11-19

PROPOSE

European Institute of Oncology

Phase 3 Not yet recruiting
95 enrolled
Breast

Breast Neoplasms

NCT03740945 2020-07-31

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

EndoCeutics Inc.

Phase 3 Withdrawn
Breast

Breast Neoplasms, Atrophic Vaginitis

NCT01376349 2019-02-07

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Alliance for Clinical Trials in Oncology

Phase 3 Completed
464 enrolled 8 charts
BreastGynecologicOther

Carcinoma, Ovarian Epithelial, Anxiety Disorders, Breast Neoplasms, Uterine Cervical Neoplasms, Depression, Fallopian Tube Neoplasms, Sexual Dysfunction, Physiological, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡